Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.64
RHHBY's Cash to Debt is ranked higher than
63% of the 812 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. RHHBY: 0.64 )
RHHBY' s 10-Year Cash to Debt Range
Min: 0.36   Max: No Debt
Current: 0.64

Equity to Asset 0.34
RHHBY's Equity to Asset is ranked higher than
51% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. RHHBY: 0.34 )
RHHBY' s 10-Year Equity to Asset Range
Min: 0.13   Max: 0.59
Current: 0.34

0.13
0.59
F-Score: 7
Z-Score: 5.01
M-Score: -2.84
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 34.30
RHHBY's Operating margin (%) is ranked higher than
98% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.15 vs. RHHBY: 34.30 )
RHHBY' s 10-Year Operating margin (%) Range
Min: 4.53   Max: 35.01
Current: 34.3

4.53
35.01
Net-margin (%) 23.15
RHHBY's Net-margin (%) is ranked higher than
96% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.37 vs. RHHBY: 23.15 )
RHHBY' s 10-Year Net-margin (%) Range
Min: -13.67   Max: 30.16
Current: 23.15

-13.67
30.16
ROE (%) 56.81
RHHBY's ROE (%) is ranked higher than
99% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.47 vs. RHHBY: 56.81 )
RHHBY' s 10-Year ROE (%) Range
Min: -16.17   Max: 82.24
Current: 56.81

-16.17
82.24
ROA (%) 17.58
RHHBY's ROA (%) is ranked higher than
97% of the 816 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.07 vs. RHHBY: 17.58 )
RHHBY' s 10-Year ROA (%) Range
Min: -5.78   Max: 17.58
Current: 17.58

-5.78
17.58
ROC (Joel Greenblatt) (%) 79.20
RHHBY's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 812 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.76 vs. RHHBY: 79.20 )
RHHBY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.9   Max: 84.52
Current: 79.2

6.9
84.52
Revenue Growth (%) -0.70
RHHBY's Revenue Growth (%) is ranked lower than
78% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. RHHBY: -0.70 )
RHHBY' s 10-Year Revenue Growth (%) Range
Min: -2.3   Max: 391.7
Current: -0.7

-2.3
391.7
EBITDA Growth (%) 5.10
RHHBY's EBITDA Growth (%) is ranked lower than
83% of the 626 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. RHHBY: 5.10 )
RHHBY' s 10-Year EBITDA Growth (%) Range
Min: -5.1   Max: 280
Current: 5.1

-5.1
280
EPS Growth (%) 8.60
RHHBY's EPS Growth (%) is ranked higher than
76% of the 628 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.00 vs. RHHBY: 8.60 )
RHHBY' s 10-Year EPS Growth (%) Range
Min: -3.8   Max: 341.1
Current: 8.6

-3.8
341.1
» RHHBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

RHHBY Guru Trades in Q3 2013

Bill Frels 610,205 sh (New)
Ken Fisher 908,434 sh (+0.28%)
» More
Q4 2013

RHHBY Guru Trades in Q4 2013

Bill Frels 1,013,940 sh (+66.16%)
Ken Fisher 906,056 sh (-0.26%)
» More
Q1 2014

RHHBY Guru Trades in Q1 2014

Ken Fisher 1,803,070 sh (+99%)
Bill Frels 2,138,396 sh (+5.45%)
» More
Q2 2014

RHHBY Guru Trades in Q2 2014

Bill Frels 2,184,810 sh (+2.17%)
Ken Fisher 1,813,443 sh (-49.71%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2014-06-30 Reduce -49.71%0.07%$35.42 - $38.07 $ 37.181%1813443
Ken Fisher 2014-03-31 Add 99%0.07%$18.14 - $38.17 $ 37.1825%1803070
Tweedy Browne 2013-06-30 Sold Out $28.92 - $32.98 $ 37.1820%0
Ken Fisher 2013-03-31 Add 634.57%0.12%$25.25 - $29.3 $ 37.1834%897861
Tweedy Browne 2012-09-30 Reduce -24.31%0.03%$20.95 - $24.07 $ 37.1866%62164
Vanguard Health Care Fund 2012-06-30 Add 543.36%2.96%$19.47 - $23.14 $ 37.1876%4273977
Ken Fisher 2012-06-30 Reduce -24.26%0.01%$19.47 - $23.14 $ 37.1876%154713
Ken Fisher 2012-03-31 Reduce -98.02%1.27%$21.55 - $22.17 $ 37.1886%204276
Tweedy Browne 2012-03-31 Reduce -22.19%0.04%$21.55 - $22.17 $ 37.1886%82130
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 21.30
RHHBY's P/E(ttm) is ranked higher than
89% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.00 vs. RHHBY: 21.30 )
RHHBY' s 10-Year P/E(ttm) Range
Min: 13.05   Max: 53.68
Current: 21.3

13.05
53.68
P/B 10.90
RHHBY's P/B is ranked higher than
52% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.40 vs. RHHBY: 10.90 )
RHHBY' s 10-Year P/B Range
Min: 2.64   Max: 17.39
Current: 10.9

2.64
17.39
P/S 5.00
RHHBY's P/S is ranked higher than
66% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.73 vs. RHHBY: 5.00 )
RHHBY' s 10-Year P/S Range
Min: 2.38   Max: 6.45
Current: 5

2.38
6.45
PFCF 18.10
RHHBY's PFCF is ranked higher than
95% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. RHHBY: 18.10 )
RHHBY' s 10-Year PFCF Range
Min: 8.6   Max: 39.65
Current: 18.1

8.6
39.65
EV-to-EBIT 14.32
RHHBY's EV-to-EBIT is ranked higher than
89% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.00 vs. RHHBY: 14.32 )
RHHBY' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 32
Current: 14.32

7.9
32
PEG 4.27
RHHBY's PEG is ranked higher than
70% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. RHHBY: 4.27 )
RHHBY' s 10-Year PEG Range
Min: 0.27   Max: 4.45
Current: 4.27

0.27
4.45
Shiller P/E 24.40
RHHBY's Shiller P/E is ranked higher than
88% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 95.10 vs. RHHBY: 24.40 )
RHHBY' s 10-Year Shiller P/E Range
Min: 13.46   Max: 110.34
Current: 24.4

13.46
110.34
Current Ratio 1.85
RHHBY's Current Ratio is ranked higher than
65% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. RHHBY: 1.85 )
RHHBY' s 10-Year Current Ratio Range
Min: 1.55   Max: 3.75
Current: 1.85

1.55
3.75
Quick Ratio 1.48
RHHBY's Quick Ratio is ranked higher than
67% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. RHHBY: 1.48 )
RHHBY' s 10-Year Quick Ratio Range
Min: 1.28   Max: 3.22
Current: 1.48

1.28
3.22

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.00
RHHBY's Dividend Yield is ranked higher than
88% of the 493 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. RHHBY: 3.00 )
RHHBY' s 10-Year Dividend Yield Range
Min: 0.74   Max: 4.55
Current: 3

0.74
4.55
Dividend Payout 0.63
RHHBY's Dividend Payout is ranked higher than
76% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.32 vs. RHHBY: 0.63 )
RHHBY' s 10-Year Dividend Payout Range
Min: 0.21   Max: 0.59
Current: 0.63

0.21
0.59
Dividend growth (3y) -7.30
RHHBY's Dividend growth (3y) is ranked higher than
71% of the 360 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. RHHBY: -7.30 )
RHHBY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 27.3
Current: -7.3

0
27.3
Yield on cost (5-Year) 2.46
RHHBY's Yield on cost (5-Year) is ranked higher than
78% of the 501 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. RHHBY: 2.46 )
RHHBY' s 10-Year Yield on cost (5-Year) Range
Min: 0.61   Max: 3.73
Current: 2.46

0.61
3.73
Share Buyback Rate -0.20
RHHBY's Share Buyback Rate is ranked higher than
81% of the 595 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.20 vs. RHHBY: -0.20 )
RHHBY' s 10-Year Share Buyback Rate Range
Min: 78.7   Max: -0.8
Current: -0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 22.70
RHHBY's Price/Tangible Book is ranked higher than
56% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.86 vs. RHHBY: 22.70 )
RHHBY' s 10-Year Price/Tangible Book Range
Min: 4.05   Max: 95.2
Current: 22.7

4.05
95.2
Price/DCF (Projected) 1.80
RHHBY's Price/DCF (Projected) is ranked higher than
86% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.60 vs. RHHBY: 1.80 )
RHHBY' s 10-Year Price/DCF (Projected) Range
Min: 1.25   Max: 7.13
Current: 1.8

1.25
7.13
Price/Median PS Value 1.20
RHHBY's Price/Median PS Value is ranked higher than
74% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.25 vs. RHHBY: 1.20 )
RHHBY' s 10-Year Price/Median PS Value Range
Min: 0.63   Max: 1.25
Current: 1.2

0.63
1.25
Price/Peter Lynch Fair Value 2.50
RHHBY's Price/Peter Lynch Fair Value is ranked higher than
74% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. RHHBY: 2.50 )
RHHBY' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.68   Max: 3.65
Current: 2.5

0.68
3.65
Price/Graham Number 4.50
RHHBY's Price/Graham Number is ranked higher than
71% of the 838 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.75 vs. RHHBY: 4.50 )
RHHBY' s 10-Year Price/Graham Number Range
Min: 1.78   Max: 7.97
Current: 4.5

1.78
7.97
Earnings Yield (Greenblatt) 7.00
RHHBY's Earnings Yield (Greenblatt) is ranked higher than
89% of the 794 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. RHHBY: 7.00 )
RHHBY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 12.7
Current: 7

3.1
12.7
Forward Rate of Return (Yacktman) 9.27
RHHBY's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.19 vs. RHHBY: 9.27 )
RHHBY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.2   Max: 146.2
Current: 9.27

2.2
146.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, NVS, ABT » details
Traded in other countries:RO.Switzerland, ROG.Switzerland, RHO6.Germany, RHO5.Germany, RHO.Germany, 0QQ6.UK, 0QOK.UK, ROG N.Mexico
Roche was founded in 1896 and is headquartered in Basel, Switzerland and is a pharmaceutical and diagnostics company. It researches and produces medicines in oncology, infectious diseases, immunology, metabolism and neuroscience. Roche also participates in in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management. Genentech, in the United States, and Chugai Pharmaceuticals are subsidiaries of the Roche Group. The firm's business is segmented into the dharmaceuticals business and the diagnostics Business.
» More Articles for OTCPK:RHHBY

Headlines

Articles On GuruFocus.com
Tweedy Browne Global Reports its Top Five Picks of Q3 Oct 21 2014 
Widely Held Guru Stocks Trading In Europe Sep 22 2014 
Dodge & Cox Second Quarter 2014 Commentary Jul 23 2014 
Tweedy Browne Global Reports Their Second Quarter Portfolio Jul 18 2014 
Signature Select Canadian Fund's Top Holdings Jul 02 2014 
The Tweedy Browne Global Value Fund's Top First Quarter Holdings Apr 22 2014 
Most Popular International Stocks of Investment Gurus Mar 05 2014 
John Rogers' Ariel Fund Comments on Roche Feb 28 2014 
Ariel International Fund & Ariel Global Fund - Healthy Ideas Feb 28 2014 
Tweedy Browne Global Value’s Top Five Year End Stocks Jan 24 2014 


More From Other Websites
5:26 pm Roche Hldg announces debt tender offer of up to $2.2 bln Oct 29 2014
Will Teva (TEVA) Beat Q3 Earnings on Strong Generic Sales? Oct 29 2014
Ventana announces collaboration to develop companion diagnostics for ImmunoGen's targeted anticancer... Oct 28 2014
OTC Markets Group Announces Third Quarter 2014 Performance of OTCM ADR Index and OTCQX30 Index,... Oct 27 2014
OTC Markets Group Announces Third Quarter 2014 Performance of OTCM ADR Index and OTCQX30 Index,... Oct 27 2014
Will Gilead (GILD) Miss Earnings on High Operating Costs? Oct 24 2014
Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta Oct 24 2014
Pharmacyclics Up on Label Expansion Efforts for Imbruvica Oct 22 2014
NewLink-Roche Ink Deal for Oncology Candidate Development Oct 21 2014
Can Valeant's Strong Q3 Entice Allergan? Oct 20 2014
Small victories recorded in fight against Ebola Oct 20 2014
Why NewLink Genetics (NLNK) Stock Is Soaring Today Oct 20 2014
Stocks Open Quietly Mixed; Hasbro, NewLink, Akorn Rising Oct 20 2014
NewLink Genetics Announces Exclusive Worldwide Licensing Agreement for Development of NLG919, an IDO... Oct 20 2014
Pharmacyclics, Roche Ink Deal for Cancer Combo Therapy Oct 17 2014
Roche Reports Strong Sales Results for 9 Months of 2014 Oct 17 2014
Ohr Pharmaceutical's OHR-102 to Enter Phase III in 1H15 Oct 16 2014
Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® and GAZYVA® in Lymphoma and... Oct 16 2014
Swiss drug maker Roche posts flat 9-month sales Oct 16 2014
Swiss drug maker Roche posts flat 9-month sales Oct 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK